Philippe Mendels-Flandre presents and explains the partnership agreement between Lysogene, Dr. Hervé Moine and SATT Conectus Alsace thanks to the Rare Diseases Foundation. This agreement concerns the development of a gene therapy product for the treatment of patients suffering from Fragile X syndrome.
For more information, click here to read the Lysogene press release.
